



## **Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings**

May 8, 2026 8:30 PM EDT

LOS ANGELES--(BUSINESS WIRE)--May 8, 2026-- **Kairos Pharma, Ltd. (NYSE American: KAPA)**, a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday, June 29, 2026. After the meeting materials are finalized and filed with the Securities and Exchanges Commission, such materials will be mailed to shareholders.

The Company also advises its Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2025, contained an audit report from its Independent Registered Public Accounting Firm with an explanatory paragraph emphasizing that the Consolidated Financial Statements were prepared assuming that the Company will continue as a going concern. Release of this information is required by Section 610(b) of the NYSE American Company Guide and does not reflect any change or amendment to any of the Company's filings for the fiscal year ended December 31, 2025.

### **About Kairos Pharma Ltd.**

Based in Los Angeles, California, Kairos Pharma Ltd. ([NYSE American: KAPA](#)) aims to work at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit [kairospharma.com](http://kairospharma.com).

### **CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS**

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma's prospectus and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260508364932/en/): <https://www.businesswire.com/news/home/20260508364932/en/>

### **Media and Investor Contact:**

Kairos Pharma, Ltd.  
Investor Relations  
Email: [investors@kairospharma.com](mailto:investors@kairospharma.com)

Source: Kairos Pharma, Ltd